Jessica C. Hassel, MD, of University Hospital Heidelberg, discusses phase III results of a study that compared tebentafusp, a bispecific fusion protein, with investigator’s choice in patients with metastatic uveal melanoma.
Archive | Video Reports
Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma
Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF-mutated melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments
Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Luke on the Importance of BRAF in Melanoma
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the importance of BRAF in melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
